A Personalized Approach to Managing Patients with Uncontrolled Asthma

Asthma is increasingly understood as a highly heterogeneous disorder, with variations in underlying immunologic pathways that contribute to an array of inflammatory phenotypes. These phenotypes can be grouped as type 2 (T2) or non-type 2. Knowledge of specific interleukins and cells has led to development of specific, targeted treatments that can safely improve patients’ symptoms and quality of life. This educational activity has been developed to increase clinicians’ understanding of new targeted therapies and how they may be used in personalized, effective asthma management.